Compare CHGA & VVOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHGA | VVOS |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 2.6M |
| IPO Year | 2015 | 2020 |
| Metric | CHGA | VVOS |
|---|---|---|
| Price | $1.41 | $0.13 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $2.12 |
| AVG Volume (30 Days) | 69.4K | ★ 1.7M |
| Earning Date | 11-13-2026 | 11-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.18 | 6.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $17,443,000.00 |
| Revenue This Year | N/A | $24.92 |
| Revenue Next Year | N/A | $56.44 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 16.05 |
| 52 Week Low | $0.25 | $0.13 |
| 52 Week High | $3.02 | $3.09 |
| Indicator | CHGA | VVOS |
|---|---|---|
| Relative Strength Index (RSI) | 34.70 | 32.30 |
| Support Level | $0.25 | $0.13 |
| Resistance Level | $2.54 | $0.55 |
| Average True Range (ATR) | 0.25 | 0.01 |
| MACD | -0.13 | 0.00 |
| Stochastic Oscillator | 0.83 | 11.97 |
Change Agents Corp is an artificial intelligence software company focused on developing agentic AI applications designed to help small businesses, brands, and content creators increase revenue, improve digital discoverability, and automate content creation. The company's current portfolio includes Beacon, an AI Search Optimization platform, and Catch-Up, an autonomous AI-powered content creation platform. Through its scalable Software-as-a-Service (SaaS) business model, it is focused on delivering AI solutions that create measurable customer value while generating recurring subscription revenue and long-term shareholder returns.
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.